Skip to main content
Erschienen in: European Radiology 8/2011

01.08.2011 | Hepatobiliary-Pancreas

Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival

verfasst von: Antoine Bouvier, Violaine Ozenne, Christophe Aubé, Jérôme Boursier, Marie Pierre Vullierme, Francine Thouveny, Olivier Farges, Valérie Vilgrain

Erschienen in: European Radiology | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims

To compare selective and non-selective TACE techniques in the treatment of HCC with a special emphasis on clinical and liver tolerance, tumour response and survival.

Methods

184 patients with advanced HCC were retrospectively included. Three different TACE techniques were compared: non selective lipiodol-chemotherapy + non selective embolisation (TACE-technique group 1), non selective lipiodol-chemotherapy + selective embolisation (group 2), and selective lipiodol-chemotherapy + selective embolisation (group 3).

Results

In multivariate analysis TACE-technique group is an independently significant prognostic factor for poor clinical tolerance, poor liver tolerance and tumour response. The rate of patients with poor clinical tolerance was lower in group 3 (27.0%) than in groups 1 (64.1%, p < 10−3) or 2 (66.7%, p < 10−3). The rate of patients with poor liver tolerance was higher in group 2 (34.0%) than in groups 1 (17.6%, p = 0.050) or 3 (6.9%, p = 0.011). The rate of patients with tumour response was higher when embolisation was selective versus non-selective, i.e., group 2 + 3 (78.7%) versus group 1 (62.5%, p = 0.054). Overall survival was not significantly different between the three groups (p = 0.383).

Conclusion

Both selective techniques resulted in better tumour response. As for improving tolerance, our study suggests that the main technical factor is the use of selective lipiodol-chemotherapy injection.
Literatur
1.
Zurück zum Zitat El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763PubMedCrossRef El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763PubMedCrossRef
2.
Zurück zum Zitat Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma Lancet 362:1907–1917CrossRef Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma Lancet 362:1907–1917CrossRef
3.
Zurück zum Zitat Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 9:739–745PubMedCrossRef Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 9:739–745PubMedCrossRef
4.
Zurück zum Zitat Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival. Hepatology 37:429–442PubMedCrossRef Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival. Hepatology 37:429–442PubMedCrossRef
5.
Zurück zum Zitat Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261CrossRef Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261CrossRef
6.
Zurück zum Zitat Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J, Barcelona Liver Cancer Group (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739PubMedCrossRef Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J, Barcelona Liver Cancer Group (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739PubMedCrossRef
7.
Zurück zum Zitat Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54PubMedCrossRef Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54PubMedCrossRef
8.
Zurück zum Zitat Beaugrand M, Trinchet JC (2007) Interventional radiology as a fine art. J Hepatol 46:362–364PubMedCrossRef Beaugrand M, Trinchet JC (2007) Interventional radiology as a fine art. J Hepatol 46:362–364PubMedCrossRef
9.
Zurück zum Zitat Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, Kim WT (2008) Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol 9:534–540PubMedCrossRef Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, Kim WT (2008) Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol 9:534–540PubMedCrossRef
10.
Zurück zum Zitat Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25PubMedCrossRef Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25PubMedCrossRef
11.
Zurück zum Zitat Dharancy S, Boitard J, Decaens T, Sergent G, Boleslawski E, Duvoux C, Vanlemmens C, Meyer C, Gugenheim J, Durand F, Boillot O, Declerck N, Louvet A, Canva V, Romano O, Ernst O, Mathurin P, Pruvot FR (2007) Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. Liver Transpl 13:665–671PubMedCrossRef Dharancy S, Boitard J, Decaens T, Sergent G, Boleslawski E, Duvoux C, Vanlemmens C, Meyer C, Gugenheim J, Durand F, Boillot O, Declerck N, Louvet A, Canva V, Romano O, Ernst O, Mathurin P, Pruvot FR (2007) Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. Liver Transpl 13:665–671PubMedCrossRef
12.
Zurück zum Zitat Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K (1993) Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 188:79–83PubMed Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K (1993) Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 188:79–83PubMed
13.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma: conclusions of the Barcelona 2000 EASL Conference. J Hepatol 35:421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma: conclusions of the Barcelona 2000 EASL Conference. J Hepatol 35:421–430PubMedCrossRef
14.
Zurück zum Zitat Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236PubMedCrossRef Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236PubMedCrossRef
15.
Zurück zum Zitat Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60PubMedCrossRef Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60PubMedCrossRef
16.
Zurück zum Zitat Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127:S179–S188PubMedCrossRef Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127:S179–S188PubMedCrossRef
17.
Zurück zum Zitat Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461–469PubMedCrossRef Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461–469PubMedCrossRef
18.
Zurück zum Zitat Lu W, Li Y, He X, Chen Y (2003) Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology 50:2079–2083PubMed Lu W, Li Y, He X, Chen Y (2003) Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology 50:2079–2083PubMed
19.
Zurück zum Zitat Lesurtel M, Müllhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA (2006) Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 6:2644–2650PubMedCrossRef Lesurtel M, Müllhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA (2006) Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 6:2644–2650PubMedCrossRef
20.
Zurück zum Zitat Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, Desai NM, Chapman WC (2006) Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 203:411–420PubMedCrossRef Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, Desai NM, Chapman WC (2006) Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 203:411–420PubMedCrossRef
21.
Zurück zum Zitat Otto G, Heise M, Moench C, Herber S, Bittinger F, Schuchmann M, Hoppe-Lotichius M, Pitton M (2007) Transarterial chemoembolization before liver transplantation in 60 patients with hepatocellular carcinoma. Transplant Proc 39:537–539PubMedCrossRef Otto G, Heise M, Moench C, Herber S, Bittinger F, Schuchmann M, Hoppe-Lotichius M, Pitton M (2007) Transarterial chemoembolization before liver transplantation in 60 patients with hepatocellular carcinoma. Transplant Proc 39:537–539PubMedCrossRef
Metadaten
Titel
Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival
verfasst von
Antoine Bouvier
Violaine Ozenne
Christophe Aubé
Jérôme Boursier
Marie Pierre Vullierme
Francine Thouveny
Olivier Farges
Valérie Vilgrain
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 8/2011
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-011-2118-2

Weitere Artikel der Ausgabe 8/2011

European Radiology 8/2011 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.